Cargando…

Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma

B and T lymphocyte attenuator (BTLA) is a newly identified immune checkpoint molecular belonging to the CD28 immunoglobulin superfamily. However, the expression and clinical value of BTLA in skin cutaneous melanoma (SKCM) has not been widely characterized. We found that BTLA levels were upregulated...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Xubin, Song, Jingjing, Chen, Buran, Qi, Yufeng, Jiang, Wenjie, Li, Huihui, Zheng, Danni, Wang, Yinghao, Zhang, Xiaohua, Liu, Haiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953043/
https://www.ncbi.nlm.nih.gov/pubmed/33718105
http://dx.doi.org/10.3389/fonc.2020.592811
_version_ 1783663851991990272
author Dong, Xubin
Song, Jingjing
Chen, Buran
Qi, Yufeng
Jiang, Wenjie
Li, Huihui
Zheng, Danni
Wang, Yinghao
Zhang, Xiaohua
Liu, Haiguang
author_facet Dong, Xubin
Song, Jingjing
Chen, Buran
Qi, Yufeng
Jiang, Wenjie
Li, Huihui
Zheng, Danni
Wang, Yinghao
Zhang, Xiaohua
Liu, Haiguang
author_sort Dong, Xubin
collection PubMed
description B and T lymphocyte attenuator (BTLA) is a newly identified immune checkpoint molecular belonging to the CD28 immunoglobulin superfamily. However, the expression and clinical value of BTLA in skin cutaneous melanoma (SKCM) has not been widely characterized. We found that BTLA levels were upregulated in metastatic melanoma compared to normal skin tissues and primary melanoma. Higher BTLA was also correlated with improved prognosis in SKCM based on several datasets. The multivariate Cox regression model revealed that BTLA was an independent survival indicator in metastatic melanoma. Tumor microenvironment analysis indicated BTLA was positively associated with the infiltrating levels of different immune cells and the activity of the anti-cancer immunity cycle. Importantly, BTLA accurately predicted the outcome of melanoma patients treated with MAGE-A3 blocker or first-line anti-PD-1. The present findings disclose that BTLA is a reliable biomarker for prognosis and immunotherapeutic response and might contribute to developing novel SKCM immunological treatment strategies.
format Online
Article
Text
id pubmed-7953043
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79530432021-03-13 Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma Dong, Xubin Song, Jingjing Chen, Buran Qi, Yufeng Jiang, Wenjie Li, Huihui Zheng, Danni Wang, Yinghao Zhang, Xiaohua Liu, Haiguang Front Oncol Oncology B and T lymphocyte attenuator (BTLA) is a newly identified immune checkpoint molecular belonging to the CD28 immunoglobulin superfamily. However, the expression and clinical value of BTLA in skin cutaneous melanoma (SKCM) has not been widely characterized. We found that BTLA levels were upregulated in metastatic melanoma compared to normal skin tissues and primary melanoma. Higher BTLA was also correlated with improved prognosis in SKCM based on several datasets. The multivariate Cox regression model revealed that BTLA was an independent survival indicator in metastatic melanoma. Tumor microenvironment analysis indicated BTLA was positively associated with the infiltrating levels of different immune cells and the activity of the anti-cancer immunity cycle. Importantly, BTLA accurately predicted the outcome of melanoma patients treated with MAGE-A3 blocker or first-line anti-PD-1. The present findings disclose that BTLA is a reliable biomarker for prognosis and immunotherapeutic response and might contribute to developing novel SKCM immunological treatment strategies. Frontiers Media S.A. 2021-02-26 /pmc/articles/PMC7953043/ /pubmed/33718105 http://dx.doi.org/10.3389/fonc.2020.592811 Text en Copyright © 2021 Dong, Song, Chen, Qi, Jiang, Li, Zheng, Wang, Zhang and Liu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Dong, Xubin
Song, Jingjing
Chen, Buran
Qi, Yufeng
Jiang, Wenjie
Li, Huihui
Zheng, Danni
Wang, Yinghao
Zhang, Xiaohua
Liu, Haiguang
Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma
title Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma
title_full Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma
title_fullStr Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma
title_full_unstemmed Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma
title_short Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma
title_sort exploration of the prognostic and immunotherapeutic value of b and t lymphocyte attenuator in skin cutaneous melanoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953043/
https://www.ncbi.nlm.nih.gov/pubmed/33718105
http://dx.doi.org/10.3389/fonc.2020.592811
work_keys_str_mv AT dongxubin explorationoftheprognosticandimmunotherapeuticvalueofbandtlymphocyteattenuatorinskincutaneousmelanoma
AT songjingjing explorationoftheprognosticandimmunotherapeuticvalueofbandtlymphocyteattenuatorinskincutaneousmelanoma
AT chenburan explorationoftheprognosticandimmunotherapeuticvalueofbandtlymphocyteattenuatorinskincutaneousmelanoma
AT qiyufeng explorationoftheprognosticandimmunotherapeuticvalueofbandtlymphocyteattenuatorinskincutaneousmelanoma
AT jiangwenjie explorationoftheprognosticandimmunotherapeuticvalueofbandtlymphocyteattenuatorinskincutaneousmelanoma
AT lihuihui explorationoftheprognosticandimmunotherapeuticvalueofbandtlymphocyteattenuatorinskincutaneousmelanoma
AT zhengdanni explorationoftheprognosticandimmunotherapeuticvalueofbandtlymphocyteattenuatorinskincutaneousmelanoma
AT wangyinghao explorationoftheprognosticandimmunotherapeuticvalueofbandtlymphocyteattenuatorinskincutaneousmelanoma
AT zhangxiaohua explorationoftheprognosticandimmunotherapeuticvalueofbandtlymphocyteattenuatorinskincutaneousmelanoma
AT liuhaiguang explorationoftheprognosticandimmunotherapeuticvalueofbandtlymphocyteattenuatorinskincutaneousmelanoma